<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552080</url>
  </required_header>
  <id_info>
    <org_study_id>Syst AB + Sinus 01</org_study_id>
    <nct_id>NCT04552080</nct_id>
  </id_info>
  <brief_title>The Effect of Systemic Antibiotics on Post-surgical Complications and Patient-centered Outcomes in Patients Undergoing Implant Surgery With Guided Bone Regeneration and Simultaneous Sinus Floor Elevation</brief_title>
  <official_title>The Effect of Systemic Antibiotics on Post-surgical Complications and Patient-centered Outcomes in Patients Undergoing Implant Surgery With Guided Bone Regeneration and Simultaneous Sinus Floor Elevation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the trial is to evaluate the effect of systemic antibiotic administration&#xD;
      compared to placebo in patients undergoing oral implant therapy with simultaneous lateral&#xD;
      sinus floor elevation and guided bone regeneration (GBR) in regard to patient-centered&#xD;
      outcomes.&#xD;
&#xD;
      The secondary aims of the trial is to evaluate the effect of systemic antibiotic&#xD;
      administration on postsurgical complications, in patients undergoing oral implant therapy&#xD;
      with simultaneous lateral approach sinus floor elevation and guided bone regeneration (GBR).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-centered Outcomes - 1</measure>
    <time_frame>days 1-7 and 14</time_frame>
    <description>Change in visual analogue scores (VAS) on the wound (pain, swelling, bruising, haematoma, bleeding) Intensity of bleeding, swelling, pain and bruising on a score from 1(mild) to 10(severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-centered Outcomes - 2</measure>
    <time_frame>days 1-7 and 14</time_frame>
    <description>Change in discomfort of the sinuses (nosebleed, nasal congestion, rhinorrhea, feeling of pressure, hyposmia)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Patients Undergoing Oral Implant Therapy</condition>
  <arm_group>
    <arm_group_label>Test: Amoxicillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Preoperatively antibiotics of 2 g amoxicillin 1 hour prior to standard implant placement and sinus floor Elevation will be administered. An additional single dose of 500 mg of amoxicillin will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.</description>
    <arm_group_label>Test: Amoxicillin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Preoperatively a placebo of 2 g will be administered. An additional single dose of 500 mg of placebo will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.</description>
    <arm_group_label>Comparator: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Medically healthy adult: ASA (American Society of Anesthesiologists) classification&#xD;
             I-II, age ≥ 21 years old&#xD;
&#xD;
          2. Non-smoker, previous smoker (quit ≥ 5 years); light smoker with less than 10&#xD;
             cigarettes/ day&#xD;
&#xD;
          3. Not allergic to Amoxicillin/Penicillin antibiotics, NSAIDS (Nonsteroidal&#xD;
             anti-inflammatory drugs) or corn-starch&#xD;
&#xD;
          4. Edentulous spaces in the posterior maxilla in one or 2 posterior quadrants with an&#xD;
             alveolar bone defect requiring sinus floor elevation and allowing implant placement of&#xD;
             up to 3 dental implants and simultaneous GBR (residual crest height 3-5 mm; per&#xD;
             implant site (Felice et al. 2012; Park et al. 2019).&#xD;
&#xD;
          5. Absence of signs of pathology of the sinus membrane and acute sinusitis requiring&#xD;
             ongoing management -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medically compromised subjects (ASA classification III-V)&#xD;
&#xD;
          2. General contraindications against implant treatment or augmentative procedures (e.g.&#xD;
             immunodeficiency, advanced systemic diseases, corticosteroid medication)&#xD;
&#xD;
          3. Those taking Bisphosphonates/anti-angiogenic/RANKL (Receptor activator of nuclear&#xD;
             factor kappa-Β Ligand) inhibitor medications or receiving local radio-therapy&#xD;
&#xD;
          4. Heavy smoker or previous heavy smoker (quit &lt; 5 years; ≥ 10 cigarettes/day)&#xD;
&#xD;
          5. Allergic to Amoxicillin or Penicillin antibiotics, NSAIDS and / or corn starch&#xD;
&#xD;
          6. Use of any form of antibiotics in the last 3 months or subjects requiring regular&#xD;
             antibiotic prophylaxis prior to dental treatment&#xD;
&#xD;
          7. Pregnant or breast feeding. Self-declared intend to conceive (A pregnancy test will be&#xD;
             performed for all female patients).&#xD;
&#xD;
          8. Need for 2 stage sinus augmentation&#xD;
&#xD;
          9. Acute or unmanaged symptomatic sinusitis&#xD;
&#xD;
         10. Type 1 implant placement (immediate implant placement following extraction)&#xD;
&#xD;
         11. Need for simultaneous soft tissue augmentation&#xD;
&#xD;
         12. Residual bone height of &gt; 5mm.&#xD;
&#xD;
         13. Subjects aged &lt; 21 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

